^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Bladder Cancer

    Related cancers:
    22h
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    1d
    Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (clinicaltrials.gov)
    P3, N=808, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv)
    1d
    Interstitial cystitis-related gene CCDC8 accelerates tumorigenesis by participating in CUL7-mediated degradation of P53 in bladder cancer. (PubMed, Oncogene)
    Pharmacological inhibition of neddylation with MLN4924 restored P53 levels and reversed the oncogenic effects of CCDC8 both in vitro and in vivo. Together, these findings highlight a novel mechanism of P53 regulation in bladder cancer, position CCDC8 as a potential biomarker and therapeutic target, and suggest a molecular link between chronic bladder inflammation and malignant transformation.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CUL7 (Cullin 7)
    |
    TP53 wild-type
    |
    pevonedistat (MLN4924)
    1d
    FAPI PET RDRC: Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jul 2026 --> Jun 2025
    Trial primary completion date
    1d
    BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P=N/A, N=4, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    FGFR3 mutation
    |
    Truseltiq (infigratinib)
    1d
    Uncommon Presentation of Primary Bladder Signet Ring Cell Carcinoma With Peritoneal Carcinomatosis: A Rare Case Report. (PubMed, Case Rep Urol)
    Despite peritoneal carcinomatosis, the patient responded to cisplatin/gemcitabine chemotherapy and immunotherapy, demonstrating tumor shrinkage on follow-up imaging. This case highlights the diagnostic challenges of SRCC due to its nonspecific symptoms and potential histological overlap with other metastatic gastrointestinal tumors. Early recognition and a multidisciplinary approach are critical for improving patient outcomes.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CDX2 (Caudal Type Homeobox 2)
    |
    PD-L1 expression • ER negative
    |
    cisplatin • gemcitabine
    1d
    Predicting BCG Response (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Dec 2027 --> Feb 2030 | Trial primary completion date: Apr 2027 --> Feb 2030
    Trial completion date • Trial primary completion date
    2d
    A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=450, Active, not recruiting, Cedars-Sinai Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Jul 2026
    Enrollment closed • Trial completion date
    2d
    A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Feb 2026 --> Aug 2028 | Trial primary completion date: Feb 2026 --> Aug 2028
    Trial completion date • Trial primary completion date
    2d
    A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=3000, Not yet recruiting, Pfizer
    New trial • HEOR • Real-world evidence
    2d
    A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Dec 2027 --> Feb 2029 | Trial primary completion date: Dec 2027 --> Feb 2029
    Trial completion date • Trial primary completion date